InterVenn Biosciences Presents Results of DAWN IO Melanoma as a Novel Liquid Biopsy Test for the Treatment of Cancer at ASCO 2022
Shots:
- The new results from the retrospective validation study of the DAWN IO Melanoma test in 205 patients with advanced melanoma. The study was conducted in collaboration with MGH
- The results demonstrated a glycoproteomic biomarker signature in MM patients as likely or not to benefit from ICIs while the unlikely to benefit group showed an m-PFS of 2.5mos. vs 17.34mos. for the likely to benefit group, 12% of patients were unlikely to respond while 10% were classified as indeterminate
- InterVenn is starting the recruitment for HELIOS-001 to support further development of DAWN in patients with advanced malignancies who will begin ICI treatment. CLIA allows InterVenn's clinical laboratory to do high-complexity tests
Ref: Businesswire | Image: InterVenn
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
